Endo announces private offering of $400 million senior unsecured notes

Nov 15 2010

Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.  

Endo intends to use the net proceeds of this offering to partially finance the pending acquisition of Qualitest Pharmaceuticals, and to pay related fees and expenses. This offering is not conditioned on the acquisition of Qualitest and if it is not consummated, the proceeds from this offering would instead be used for general corporate purposes.

The notes and the related subsidiary guarantees have not been registered under the Securities Act of 1933 as amended or any applicable state securities laws, and will be offered only to qualified institutional buyers in reliance on Rule 144A, and outside the United States in compliance with Regulation S under the Securities Act. Unless so registered, the notes and the related subsidiary guarantees may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.